My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  alliance managers  partners  partner  alliance manager  ecosystem  partnerships  The Rhythm of Business  partnership  Jan Twombly  biopharma  governance  Eli Lilly and Company  Strategic Alliance Magazine  Vantage Partners  IBM  IoT  ASAP BioPharma Conference  strategy  healthcare  NetApp  2015 ASAP Global Alliance Summit  Cisco  cloud  communication  digital transformation 

Making Adjustments: ASAP Global Alliance Summit Now in June!

Posted By Michael Leonetti, CSAP, Monday, March 9, 2020

We’ve all had the experience of an unexpected event that suddenly threw a wrench into our alliances or our lives. Depending on the nature of the event, its magnitude, and how close to home it hits, we generally do our best to understand how the landscape has changed, adjust to the implications, make accommodations, and move forward. Reality may defy our hopes and expectations, but we pick up the pieces, dust ourselves off, and keep getting up in the morning amid the now-altered environment.

So it is with the coronavirus, or COVID-19, whose effects worldwide have already proven serious. Our hearts go out to all those who have been directly affected by this virus, especially the families of those who have died from it around the globe. In addition, this contagious disease—and the fear of it—has already had a significant economic impact, including declines in business and vacation travel and the cancellation or postponement of a number of conventions, conferences, and trade shows in various industries. Most organizations have been forced to respond in some way, whether to shift events to alternative dates or from physical to virtual, to curtail travel to safeguard their people, or to try to limit the damage to their bottom line. Or all of the above.

We at ASAP have faced these challenges as well, resulting in the difficult decision to reschedule our Global Alliance Summit, which had been scheduled for next week, to June 23–25 in Tampa, Florida. In the great scheme of things this move may barely register, but for a member organization like ours, as you can imagine, it’s a big deal. Shifting the Summit to new dates has required a huge and immediate lift on the part of ASAP staff and board, which is ongoing as I write this.

The good news is, the show will go on! I’m very happy that we were able to secure the original conference venue, the Renaissance Tampa International Plaza Hotel, for our late-June dates. I’m even more pleased to report that at present, nearly 75 percent of our presenters, panelists, and moderators have confirmed that they’ll be there.

What this means is that we’ll still have a terrific program, as planned—a program that, as always, includes presentations by some of the alliance and partnering profession’s best and brightest minds and leading lights, including these:

  • A keynote presentation by Steve Steinhilber, global vice president, ecosystems and business development, at Equinix: “Creating Alliances and Digital Ecosystem Capabilities in an Increasingly Platform Enabled and Interconnected World.” Steve ran alliances at Cisco for a number of years, and while there authored the influential book Strategic Alliances: Three Ways to Make Them Work (2008). He was also among those interviewed for our Q1 2020 cover story in Strategic Alliance Quarterly on the rise and far-reaching effects of ecosystems in nearly every industry, and his insights into this important and growing area are sure to be valuable and applicable to any industry.
  • A fascinating panel moderated by Adam Kornetsky of Vantage Partners titled “Big Pharma M&A and Alliance Portfolios: What’s at the End of the Rainbow?” This interactive discussion will feature panelists including Mark Coflin, CSAP, vice president and head of global alliances at Takeda Pharmaceuticals; Dana Hughes, vice president of integration management and alliance management at Pfizer; and Jeffrey C. Hurley, senior director, GBD global alliance lead at Takeda. These longtime ASAP members will share their recent M&A experiences, provide insights into how alliance portfolios have been managed through the transaction process, and engage participants in sharing additional perspectives critical for unlocking and maximizing the full value of an alliance portfolio.
  • A presentation by Dan Rippey, director of engineering for Microsoft’s One Commercial Partner program, and Amit Sinha, chief customer officer and cofounder of WorkSpan, called “How the Microsoft Partner-to-Partner Program Is Disrupting the Way Technology Companies Are Leveraging the Power of Ecosystems for Business Growth, Customer Acquisition, and Gaining a Competitive Advantage.” With the rise of ecosystems has come the increasing deployment of partner-to-partner (P2P) programs, and Microsoft’s may be the largest on the planet, connecting partners directly with each other to deliver value to customers without Microsoft’s intervention. Powered by WorkSpan Ecosystem Cloud, this program increases profitability by selling solutions from one or more of Microsoft’s partners, achieving faster time-to-market by leveraging prebuilt joint solutions, closing larger deals, and reaching more customers by co-selling with other Microsoft partners for a bigger joint pipeline. This new model of partnering has wide applicability and Dan and Amit’s description of how it works is a must-hear.
  • Another terrific panel moderated by Jan Twombly, president of The Rhythm of Business, called “Biopharma Commercial Alliance Management Challenges.” Panelists will include Brooke Paige, CSAP, ASAP board chair and former vice president of alliance management at Pear Therapeutics; and David S. Thompson, CSAP, chief alliance officer at Eli Lilly and Company. In the long life of a successful biopharma alliance, the commercialization phase brings its own particular challenges and problems. This panel promises to be a lively discussion of such topics as how alliance managers deliver value in a commercial alliance, considerations for driving alignment in local geographies and at a corporate level, aspects of alliance governance to get right to maximize value, and much more.

I’m not indulging in hyperbole when I say that these are just a very few of the highlights. Again,  more than three-quarters of the original Summit agenda is planned  to remain intact—including preconference workshops, single-speaker presentations, illuminating panel discussions, and of course, valuable networking opportunities.

We know there are many factors governing decisions on where to travel and why—especially under current conditions. But we’re confident that even after shifting to the June dates, we’ll be fielding a stellar lineup at the Summit in Tampa—one you’ll want to be present for. If you haven’t registered yet and/or for whatever reason were uncertain about attending in March, you now have some extra time to decide.

Additionally, the Renaissance has set up a new block of rooms at our discounted rate of $219.00+ per night. To book your room for the new conference dates, please click on the link below:

https://www.marriott.com/event-reservations/reservation-link.mi?id=1583953400577&key=GRP&app=resvlink

Let’s all try to plan for normal again! Won’t you join us? I hope to see you in Tampa!

Tags:  alliances  Amit Sinha  biopharma  Brooke Paige  Dan Rippey  Dana Hughes  David Thompson  Ecosystems  Eli Lilly and Company  Equinix  Jan Twombly  Jeffrey Hurley  Mark Coflin  Microsoft  P2P  partners  Pfizer  Steve Steinhilber  Takeda  The Rhythm of Business  Vantage Partners  WorkSpan 

Share |
PermalinkComments (0)
 

Change as a Constant: A Timely Session Planned for the ASAP BioPharma Conference

Posted By Geena B. Richards and Cynthia B. Hanson, Tuesday, October 23, 2018

Managing cycles of change is a session theme certain to unpack a profusion of thought-provoking ideas at the 2018 ASAP BioPharma Conference “Creating Valuable and Innovative Partnerships by Driving the Alliance Mindset,” September 24-26 at the Hyatt Regency Boston in Boston, Massachusetts USA. When change is afoot, alliance managers must learn how to quickly shift, dance, adapt, and evolve to keep pace in today’s meteoric biopharma partnering climate. How do alliance managers maintain an alliance mindset while negotiating fast-paced strategic changes, organizational shifts, and the introduction of new leadership? In a buzz of constant change, how do teams continue to listen to future needs? These are just a few of the challenges that will be addressed in the session “Leading Alliance Management amidst Shifting Corporate Strategy,” moderated by Andy Eibling, CSAP, senior partner at Forty86 Consulting Group. He will bring four panelists together to tackle this topic along with audience participation: Nick Dunscombe, vice president of business & commercial development at Astellas Pharma Europe; Mojgan Hossein-Nia, vice president, head of the R&D partnership office, Takeda; Steve Twait, CSAP, vice president alliance and integration management at AstraZeneca; Lucinda Warren, vice president business development, neuroscience, Johnson & Johnson Innovation/Janssen Business Development. Eibling recently provided a brief preview of some of the focal points the panelists plan to discuss.

What were some of the themes of this session?
Three of the four panelists have undergone significant changes in their careers. The fourth went through big organizational shifts not too long ago and has had multiple jobs within the organization. As the moderator, I will let them paint their own portrait and tell their own story and then go into targeted questions. We will discuss a lot of the problems associated with transitioning and how the panelists have solved them. We plan to stay within the alliance mindset and talk about how to ensure that the right mindset is in place as your alliance goes through strategic changes or as you are introduced into a new organization. Those changes could be an organizational shift from centralized to decentralized or a move to organize by therapeutic area to business unit. Changes to alliances, such as asset divestitures, will be covered. We will talk a little bit about tools and technology and how they are being used to learn and share expertise. As we talk about changes in strategies, we will get into metrics and how you can leverage them to ensure that you stay true to the alliances and their objectives. What metrics are companies incorporating to measure not just alliance health, but collaboration value? Another topic is how to design a Center of Excellence. This group has lots of expertise and different types of experiences.

What are some of the biggest challenges pharma alliance managers face today when dealing with corporate restructuring, both internally and externally?
That’s one of the themes we will address. As your organization shifts, by business unit or a move to a decentralized structure, what impact does that have? How does that change impact how your team performs? Constant change is the norm today as corporations strive to deliver much-needed innovative therapies to patients, increase revenues, and provide shareholder value. All the change we are talking about could be interpreted as ecosystem change for lasting solutions. The answers need to be flexible, not only relating to what you are going through now but predicting the next change as the pendulum swings. When the bowl of asset divestment wanes, what’s next? And do you have the right skills for the coming changes? What are the trends in non-traditional partnerships? Is the alliance language the same in the collaboration lifecycle?

What about adapting to changes in company culture? Will you be discussing these types of changes as well?
We are going to make sure to incorporate questions from the audience, and I wouldn’t be surprised if that comes up as a question. Nick Dunscombe, one of the panelists, just moved from a British to a Japanese company with a strong presence in the United States. He moved from alliance management at AstraZeneca to Astellas. Corporate culture might be something he could address. How do you apply what you know, what you learn, and how you shift? He will discuss best practices and the differences in the companies. Also, how do you adapt and how do you do it differently? What things worked in the past?

For more discussion of critical biopharma partnering topics and conference coverage, check out the Q2 and Q3 2018 issues of Strategic Alliance Magazine and the August 2018 issue of eSAM Plus.

Tags:  2018 ASAP BioPharma Conference  alliance manager  alliance mindset  Andy Eibling  Astellas  AstraZeneca  corporate culture  corporate restructuring  Johnson & Johnson Innovation  Lucinda Warren  Mojgan Hossein-Nia  Nick Dunscombe  non-traditional partnerships  Steve Twait  strategic challenges  Takeda 

Share |
PermalinkComments (0)
 

Change as a Constant: A Timely Session Planned for the Upcoming ASAP BioPharma Conference

Posted By Geena B. Richards and Cynthia B. Hanson, Thursday, September 20, 2018
Updated: Monday, September 17, 2018

Managing cycles of change is a session theme certain to unpack a profusion of thought-provoking ideas at the 2018 ASAP BioPharma Conference “Creating Valuable and Innovative Partnerships by Driving the Alliance Mindset,” September 24-26 at the Hyatt Regency Boston in Boston, Massachusetts USA. When change is afoot, alliance managers must learn how to quickly shift, dance, adapt, and evolve to keep pace in today’s meteoric biopharma partnering climate. How do alliance managers maintain an alliance mindset while negotiating fast-paced strategic changes, organizational shifts, and the introduction of new leadership? In a buzz of constant change, how do teams continue to listen to future needs? These are just a few of the challenges that will be addressed in the session “Leading Alliance Management amidst Shifting Corporate Strategy,” moderated by Andy Eibling, CSAP, senior partner at Forty86 Consulting Group. He will bring four panelists together to tackle this topic along with audience participation: Nick Dunscombe, vice president of business & commercial development at Astellas Pharma Europe; Mojgan Hossein-Nia, vice president, head of the R&D partnership office, Takeda; Steve Twait, CSAP, vice president alliance and integration management at AstraZeneca; Lucinda Warren, vice president business development, neuroscience, Johnson & Johnson Innovation/Janssen Business Development. Eibling recently provided a brief preview of some of the focal points the panelists plan to discuss.

What are some of the themes of this session?
Three of the four panelists have undergone significant changes in their careers. The fourth went through big organizational shifts not too long ago and has had multiple jobs within the organization. As the moderator, I will let them paint their own portrait and tell their own story and then go into targeted questions. We will discuss a lot of the problems associated with transitioning and how the panelists have solved them. We plan to stay within the alliance mindset and talk about how to ensure that the right mindset is in place as your alliance goes through strategic changes or as you are introduced into a new organization. Those changes could be an organizational shift from centralized to decentralized or a move to organize by therapeutic area to business unit. Changes to alliances, such as asset divestitures, will be covered. We will talk a little bit about tools and technology and how they are being used to learn and share expertise. As we talk about changes in strategies, we will get into metrics and how you can leverage them to ensure that you stay true to the alliances and their objectives. What metrics are companies incorporating to measure not just alliance health, but collaboration value? Another topic is how to design a Center of Excellence. This group has lots of expertise and different types of experiences.

What are some of the biggest challenges pharma alliance managers face today when dealing with corporate restructuring, both internally and externally?
That’s one of the themes we will address. As your organization shifts, by business unit or a move to a decentralized structure, what impact does that have? How does that change impact how your team performs? Constant change is the norm today as corporations strive to deliver much-needed innovative therapies to patients, increase revenues, and provide shareholder value. All the change we are talking about could be interpreted as ecosystem change for lasting solutions. The answers need to be flexible, not only relating to what you are going through now but predicting the next change as the pendulum swings. When the bowl of asset divestment wanes, what’s next? And do you have the right skills for the coming changes? What are the trends in non-traditional partnerships? Is the alliance language the same in the collaboration lifecycle?

What about adapting to changes in company culture? Will you be discussing these types of changes as well?
We are going to make sure to incorporate questions from the audience, and I wouldn’t be surprised if that comes up as a question. Nick Dunscombe, one of the panelists, just moved from a British to a Japanese company with a strong presence in the United States. He moved from alliance management at AstraZeneca to Astellas. Corporate culture might be something he could address. How do you apply what you know, what you learn, and how you shift? He will discuss best practices and the differences in the companies. Also, how do you adapt and how do you do it differently? What things worked in the past?

For more discussion of critical biopharma partnering topics and conference coverage, check out the Q2 and Q3 2018 issues of Strategic Alliance Magazine and the August 2018 issue of eSAM Plus.

Tags:  2018 ASAP BioPharma Conference  alliance manager  alliance mindset  Andy Eibling  Astellas  AstraZeneca  corporate culture  corporate restructuring  Johnson & Johnson Innovation  Lucinda Warren  Mojgan Hossein-Nia  Nick Dunscombe  non-traditional partnerships  Steve Twait  strategic challenges  Takeda 

Share |
PermalinkComments (0)
 

2015 ASAP European Alliance Summit Echoes the Ecosystem Partnering Theme

Posted By Cynthia B. Hanson, Monday, November 9, 2015

The European Union is following the United States’ lead in cross-industry partnering. Partnering executives from across Europe convened to explore “The New Ecosystem for Partnerships” at the October 15-16, 2015 ASAP European Alliance Summit, held at the NH Amsterdam Grand Hotel in Amsterdam. Co-sponsored by Thought Leader Global, which specializes in organizing corporate events across the spectrum of corporate strategy, business development, and finance, the event drew about 60 attendees, most of whom were heads of strategic alliances and partnerships from all kinds of industries, primarily multi-nationals. 

The “successful partnership” between the two co-sponsors created a “great opportunity” for companies looking to learn from “different types of collaborations,” said ASAP Chairman of the Board Christine Carberry, CSAP, senior vice president, quality, technical operations, program & alliance management, at FORUM Pharmaceuticals, who attended the gathering. “In the past, it was biopharma-to-biopharma, high tech-to-high tech. We are now seeing much more partnering diversity across industries, including the service sector, academic institutions, and healthcare providers,” she explained.  “We are starting to get a much more diverse membership in ASAP and with people who are newer in alliance management.” 

Some 20 percent of ASAP membership is European-based, and the alliance community in Europe is an area of growth, said Carberry. 

“People are beginning to realize they need to build alliance management capability across their entire organization. And people are beginning to get interested in how to provide more resources, training, and guidance to those who need those skills and capabilities because they interact with partners and collaborations, “ Carberry added. 

Cross-industry collaboration is definitely happening in Europe, “but probably at a slower rate than the US,” agreed Scott Rogers, Thought Leader Global’s project manager. “One of the strengths of this event is benchmarking both within and outside your industry. So there are best practices from pharmaceutical companies managing alliances in complex ecosystems, but also strategies from IT companies handling unique technology partnerships. Terminology may sometimes differ, but essential principles remain the same.” 

Reflecting on the Summit, he said Sanofi, Ericsson, Takeda, and Unilever offered excellent presentations. Prominent manufacturing companies shared highly relevant experiences, and mature and emerging alliance managers gained best practices and possible networking connections with fellow attendees. “We reviewed the evaluation forms and we’re happy to report that attendees gave positive reviews to all the presentations, with many favoring speakers in their industry,” he added.

Summit attendees participated in sessions that spanned biopharma and high tech. Carberry singled out two sessions relating to the global trend of high tech and biopharma partnering because their convergence is requiring news skills and approaches. 

One session about R&D and strategy was given by Ingo Hoffmann, global head of strategic alliances & partner ecosystem at IBM’s Curam Solutions & Smarter Care. The other, Joint Ventures to Advance Corporate Development and Growth in New Markets” on advanced ventures and how they partner and grow, was given by Pierrick Rollet, vice president of global strategic partnerships & joint ventures at GlaxoSmithKline Vaccines. 

Carberry and Rogers agreed that the event exemplifies a win-win partnership, allowing ASAP to convene a significant contingent of its European members while also connecting with executives who are new to the association. 

“It was a high-quality event at a location well-suited for our European colleagues,” Carberry said. “I think it’s been a successful partnership between ASAP and Thought Leader Global. About half of people were familiar with ASAP.”

“This event theme fits perfectly within our portfolio, and we are able to leverage relationships from our other events to support this one,” added Rogers. “We are pleased with the ongoing collaboration between Thought Leader Global and ASAP.”

Tags:  2015 ASAP European Alliance Summit  alliance management  best practices  Christine Carberry  Ericsson  FORUM Pharmaceuticals  GlaxoSmithKline Vaccines  IBM’s Curam Solutions & Smarter Care  Ingo Hoffmann  partnering diversity  Pierrick Rollet  Sanofi  Scott Rogers  Takeda  Thought Leader Global  Unilever 

Share |
PermalinkComments (0)
 

Sharing Alliance Management Capabilities across Enterprise and Globe: Takeda’s Center of Excellence Case Study

Posted By John W. DeWitt, Friday, September 11, 2015

Organizations today are collaborating at a pace that far outstrips the available resources of most alliance management organizations. While many collaborations don’t call for a full-time alliance professional, stakeholders typically need access some level of alliance management capabilities. At Wednesday’s ASAP Leadership Forum, held on the opening day of the 2015 ASAP BioPharma Conference in Boston, I chatted with several seasoned biopharma alliance executives about how they increasingly are being pulled into advisory roles for new types of alliances—presenting exciting opportunities, yes, but piling more responsibilities onto an already heavy workload.

 

Developing a “center of excellence,” or COE, for alliance management represents an increasingly common approach for distributing the toolkits and tool-using expertise of alliance management more broadly across the organization for the use of both dedicated and part-time alliance managers. Takeda, Japan’s largest pharma company with ¥1.778 billion  annual revenues, built an ASAP Excellence Award-winning COE guided by alliance management practice but heavily engaging stakeholders outside the function in the COE’s design. On Thursday afternoon, three Takeda executives shared their methodology, challenges, and results in a conference session titled “From the User’s Perspective: An Alliance Management Center of Excellence Success Story.”

 

Two of Takeda’s senior directors of global alliance management, Gray Hulick, CA-AM, and Jenny Rohde, CA-AM, set the stage by describing the COE’s development and the cross-functional team involved. “Our main finding”—and driver of the COE—was that “Takeda didn’t have consistent approach to managing alliances,” explained Rohde. Takeda had a vision of the COE as “a hub for members to access alliance management tools, training, and share best practices, guided by an executive steering committee from across the organization, inclusive of functional area heads, and staffed across the globe.”

 

The COE was carefully designed from the end-user—meaning non-alliance executive—perspective.

 

“We did detailed needs assessments with the idea of really creating tools that our members need,” Hulick explained. “Interestingly, the needs are remarkably similar. People didn’t have access to tools, formal or informal alliance management training, and were unclear about what they were supposed to be doing in their jobs.” So for some end users, the COE’s key job was to make existing assets accessible. “We utilized in many cases tools and training we had access to—we already have toolkits focused on development and commercial partnerships.”

 

However, Takeda at that time lacked a research alliances toolkit—“something much more streamlined for research alliances,” as Hulick put it. This was developed with the deep involvement of Takeda’s third presenter—Kentaro Hashimoto, PhD, associate director of the oncology drug discovery unit in Takeda’s pharmaceutical research division. The need for the toolkit is clear. “More than 50 percent of our pipeline now comes from external partners—so as a research division this shows how important external innovation is to us,” Hashimoto said. More than 200 research alliances translated into an overwhelming task for non-professional managers. “Sometimes scientists serve not just as investigator and project manager, but also as alliance manager,” and across Takeda there was “a diversity of mindsets on how to manage alliances,” he explained. “Our vision is to have access to a worldwide network of scientific excellence” enabled by partnering excellence.

 

The toolkits—developed by the global team of end users and alliance executives that comprise the COE—were originally written in English, but then were translated by Japanese end users as a means of increasing end user ownership and making sure that the content is actionable by these end users. Takeda also has chosen not to mandate their use, but rather to create end-user pull for these resources.

 

Hashimoto shared several key lessons learned.

 

“I have to be honest, in the real world, it’s not so easy,” he said. “It really takes a long time to change mindset, people’s behavior, because they have their own experiences, and alliance managers have their own skills and experience too. So it can be difficult to move to a new way. Finding the right balance is important. You need to use alliance management toolkits and skills in the right time and right way. For example, forcing consensus (to sign the deal) at an early stage among researchers is not always the right way. You need to give them time before pushing for consensus. And governance—you can try to keep it as in the original contract, but sometimes the science brings things you didn’t realize, and you should follow the science, be flexible, even change if needed.”

 

Hashimoto emphasized that his involvement in the COE was a rewarding experience in many ways.

 

“I always enjoy working with COE core members. It was exciting to be part of this initiative.” And, he added, “From the user’s perspective in the research division, I got a chance to understand how our alliance management [capability] applies in a very objective way to our research activities. And we had the chance to develop by ourselves the toolkits and training programs to make our activities better.”

Tags:  2015 ASAP BioPharma Conference  alliance management  ASAP Excellence Award  center of excellence  COE  Gray Hulick  Jenny Rohde  Kentaro Hashimoto  Takeda  training 

Share |
PermalinkComments (0)
 
Page 1 of 2
1  |  2
For more information email us at info@strategic-alliances.org or call +1-781-562-1630